PPH vs PJP Which Pharmaceutical ETF Actually Belongs in Your Portfolio?

Two Pharma ETFs, Two Very Different Bets 📌

The pharmaceutical sector has long been a cornerstone of defensive portfolios, offering recession-resistant demand and reliable dividend income. But not all pharma ETFs are built the same.

The VanEck Pharmaceutical ETF (PPH) and the Invesco Pharmaceuticals ETF (PJP) both target drug developers and manufacturers, yet their portfolios, cost structures, and risk profiles diverge significantly. Understanding these differences is critical before committing capital.

Here's what separates them at a glance:

• PPH charges 0.36% annually and yields 2.0%
• PJP charges 0.58% and yields 0.9%
• PJP posted a 41% trailing one-year return vs. PPH's 31%
• PPH holds $1.0 billion in assets vs. PJP's $569.6 million

The question isn't which fund is "better" in isolation — it's which one aligns with your investment goals.

The Winner's Circle: Where Each Fund Excels 🏆

PPH: The Income and Cost Leader

VanEck's PPH wins on two fronts that matter enormously for long-term holders: cost efficiency and income generation. At 0.36%, its expense ratio sits 22 basis points below PJP's 0.58%. Over a 10-year horizon, that gap compounds meaningfully.

More importantly, PPH's 2.0% dividend yield more than doubles PJP's 0.9%. For retirees or income-focused investors, that distribution difference is hard to ignore.

PPH also provides global exposure — roughly 63.7% of its portfolio is U.S.-based, with the remainder spread across international pharmaceutical giants. Its top three holdings tell the story:

• Eli Lilly (LLY): 20.82%
• Merck (MRK): 13.36%
• Novo Nordisk (NVO): 5.62%

That 20.82% allocation to Eli Lilly is both a strength and a vulnerability — more on that below.

PJP: The Performance Chaser

Invesco's PJP delivered a 41% one-year return, outpacing PPH by a full 10 percentage points. Its secret? A more balanced, rules-based weighting methodology that evaluates holdings on price momentum, earnings quality, and value metrics.

PJP's top positions are notably more diversified:

• Gilead Sciences (GILD): 5.58%
• Pfizer (PFE): 5.48%
• AbbVie (ABBV): 5.46%

No single holding exceeds 6%, which reduces single-stock blowup risk. However, PJP focuses exclusively on U.S. pharmaceutical companies, sacrificing international diversification.

For investors seeking pure domestic exposure with a momentum tilt, PJP's methodology has clearly delivered — at least over the past year.

The pharmaceutical ETF debate often splits investors into two camps. Here's how both sides make their case:

Head-to-Head: The Numbers That Matter 📊

Risk-Adjusted Perspective

PJP's lower max drawdown (-17.5% vs. -20.3%) suggests better downside protection during turbulent periods. However, PPH's higher yield partially compensates for that deeper drawdown through consistent income distributions.

The 5-year growth of $1,000 tells a nuanced story: PJP's $1,722 slightly edges PPH's $1,677, but when you factor in PPH's superior dividend yield reinvested over that period, the gap narrows considerably.

The Concentration Question

PPH's 20.82% allocation to Eli Lilly is the single biggest risk factor in this comparison. If LLY stumbles — whether from pipeline failures, patent cliffs, or regulatory headwinds — PPH absorbs that pain disproportionately. PJP's balanced approach insulates against this specific risk.

That said, LLY's GLP-1 franchise (Mounjaro, Zepbound) has been a massive growth engine, and PPH holders have benefited enormously from that concentration.

Historical parallel: During the 2022 pharma selloff, concentrated pharma ETFs experienced drawdowns 3-5% deeper than their balanced counterparts — a pattern worth remembering when evaluating PPH's current positioning.

📊 In-Depth Fundamental Analysis

The Verdict: It Depends on What You're Optimizing For 🎯

There's no universal "better" ETF here — only the right tool for your specific objectives.

Choose PPH if you prioritize:

• Income generation (2.0% yield vs. 0.9%)
• Lower costs (0.36% vs. 0.58%)
• Global diversification (international pharma exposure)
• Liquidity ($1B AUM vs. $570M)
• Long-term buy-and-hold with dividend reinvestment

Choose PJP if you prioritize:

• Recent performance momentum (41% vs. 31%)
• U.S.-only exposure
• Lower concentration risk (no position above 6%)
• Rules-based, factor-driven selection
• Shallower drawdowns during corrections

The Practical Takeaway

For most long-term investors building a diversified portfolio, PPH's cost and yield advantages make it the more efficient core holding. The 22 basis point fee difference and 110 basis point yield advantage compound significantly over decades.

However, if you already hold concentrated positions in Eli Lilly or Novo Nordisk elsewhere in your portfolio, PJP's balanced approach provides better diversification within the pharma sleeve of your allocation.

⚠️ Risk reminder: Pharmaceutical ETFs face unique risks including drug pricing legislation, patent expirations, clinical trial failures, and regulatory changes. Past performance — including PJP's recent 41% run — does not guarantee future results. Always size positions according to your risk tolerance and time horizon.

📚 Further Reading

• Canadian Banc Corp's 15% Yield Target: A Deep Dive — for income investors comparing high-yield strategies
• A Divided Fed, A Hawkish Lean: What It Means for Your Portfolio — understanding how rate policy impacts sector rotation into defensives like pharma